📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
151,859
All-time analysed
43,535
Positive
6,743
Negative
92,744
Neutral
8,769
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
270 announcements match the current filters (relevance ≥ 5).
₹8,244 Cr AUM: IndoStar Q1 FY27 NIM Expands to 8.8% Amid Retail Transition
IndoStar reported a consolidated PAT of ₹11.5 Cr for Q1 FY27, recovering from a heavy loss of ₹424 Cr in the previous quarter (Q4 FY26) which was impacted by accelerated provisioning. AUM grew 6% YoY to ₹8,244 Cr, driven by the company's strategic pivot toward retail segments like Used Vehicle Finance and Micro LAP. Net Interest Margins (NIM) improved significantly to 8.8% from 6.2% YoY, supported by a reduction in borrowing costs to 9.9%. However, asset quality showed slight deterioration with Gross Stage 3 assets rising to 4.8% from 4.0% YoY.
Confidence: HIGH
What changedIndoStar has completed its transition to a retail-focused NBFC following the sale of its housing finance subsidiary, now focusing on granular, high-yield retail loans.
Why it mattersThe shift to retail is successfully expanding margins (NIM at 8.8%), but the rising Stage 3 assets indicate that credit risk management remains a critical factor for valuation re-rating.
Assets Under Management (AUM): ₹8,244 CrNet Interest Margin (NIM): 8.8%Gross Stage 3 Assets: 4.8%Capital Adequacy Ratio: 34.8%AUM vs Market Cap: 3.2xCost of Borrowings: 9.9%
📅 Short termThe stock may see neutral to slightly positive sentiment as the company returns to profitability and shows margin expansion, though asset quality trends will limit upside.
📈 Long termThe structural shift to a retail-led model with high capital adequacy provides a strong foundation for growth, provided the company can contain credit costs below 2-3%.
⚠ Risk flags
- Rising Gross Stage 3 assets (4.8%)
- High credit costs (₹81.4 Cr in Q1 FY27)
- Concentration in the Used Vehicle segment
Key Highlights
AUM increased to ₹8,244 Cr in Q1 FY27, a 6% growth compared to ₹7,783 Cr in Q1 FY26
Net Interest Margin (NIM) expanded to 8.8% from 6.2% YoY, driven by higher-yielding retail assets
Gross Stage 3 assets rose to 4.8% compared to 4.0% in the same period last year
Cost of borrowings improved to 9.9% from 10.7% in Q1 FY26
Capital Adequacy Ratio remains robust at 34.8% with a low Debt/Equity ratio of 1.54x
👀 What to Watch
Investors should monitor the stabilization of Gross Stage 3 assets and the disbursement momentum in the newly launched Micro LAP segment to gauge long-term profitability.
IndoStar Q1FY27: Disbursements up 44% to ₹1,235 Cr; PAT returns to ₹11.5 Cr
IndoStar Capital Finance reported a strong operational recovery in Q1FY27, with disbursements growing 44% YoY to ₹1,235 crore. The company returned to a profit of ₹11.5 crore after a massive loss of ₹424 crore in the preceding quarter (Q4FY26). Net Interest Income (NII) rose 39% YoY to ₹219.5 crore, aided by an 80 bps reduction in the weighted average cost of funds to 9.9%. While AUM growth was modest at 6% YoY reaching ₹8,244 crore, the retail pivot is evident with Micro LAP growing 24% QoQ.
Confidence: HIGH
What changedThe company has successfully returned to profitability after a large one-time loss in Q4FY26 and has accelerated its retail disbursement engine.
Why it mattersThe results demonstrate the execution of the company's strategy to pivot from corporate lending to high-yield retail segments like Used CV and Micro LAP, while simultaneously lowering borrowing costs.
Disbursements: ₹1,235 croreAUM: ₹8,244 croreNet Interest Income: ₹219.5 croreCost of Funds: 9.9%Gross Stage 3 Assets: 4.84%AUM vs Market Cap: 3.2x
📅 Short termThe return to profitability and strong disbursement growth are likely to be viewed positively by the market in the coming weeks.
📈 Long termThe structural shift to a granular retail portfolio and lower leverage (1.5x) positions the company for more stable, albeit lower-margin than corporate, long-term growth.
⚠ Risk flags
- Elevated Gross Stage 3 assets at 4.84%
- Dependency on bank funding lines for liquidity
- High competitive intensity in the Used CV segment
Key Highlights
Disbursements reached ₹1,235 crore, a 44% increase compared to Q1FY26.
Net Interest Income (NII) grew 39% YoY to ₹219.5 crore, supported by improved yields.
Weighted average cost of funds declined by 80 basis points YoY to 9.9%.
Micro LAP segment showed significant momentum with 24% QoQ growth.
Asset quality remains a monitorable with Gross Stage 3 assets at 4.84% and Net Stage 3 at 2.48%.
👀 What to Watch
Investors should monitor the stabilization of asset quality (GS3 at 4.84%) and whether the company can maintain the 9.1% incremental cost of funds to sustain NIMs.
INDOSTAR Q1 FY27: Disbursements Up 44% to ₹1,235 Cr; Returns to Profitability
IndoStar Capital Finance reported a turnaround in Q1 FY27 with a Profit After Tax (PAT) of ₹11 crore, following a significant loss of ₹424 crore in the preceding quarter. Disbursements grew strongly by 44% YoY to ₹1,235 crore, driven by a strategic pivot toward retail segments like Used Vehicle Finance and Micro LAP. Net Interest Income (NII) rose 39% YoY to ₹219 crore, supported by an 80 bps reduction in the weighted average cost of funds to 9.9%. Asset quality remains a monitorable area with Gross Stage 3 assets at 4.84%.
Confidence: HIGH
What changedThe company has successfully returned to profitability after a heavy loss in Q4 FY26 and has accelerated its retail disbursement growth to 44% YoY.
Why it mattersThis performance validates IndoStar's strategic shift from corporate lending to a granular, high-yield retail model, which is critical for long-term ROA improvement and valuation re-rating.
Disbursements (Q1 FY27): ₹1,235 croreAssets Under Management (AUM): ₹8,244 croreNet Interest Income (YoY Growth): 38.9%Gross Stage 3 Assets: 4.84%Cost of Funds: 9.9%AUM vs TTM Revenue: 319%
📅 Short termThe stock may react positively to the turnaround from loss to profit and the robust 44% growth in disbursements.
📈 Long termThe structural shift to a retail-focused NBFC (Used CV and Micro LAP) is progressing well, which could lead to more stable and higher-margin earnings over the next several quarters.
⚠ Risk flags
- Elevated Gross Stage 3 assets at 4.84%
- Dependency on bank funding lines for liquidity
- Execution risk in scaling the Micro LAP business
Key Highlights
Disbursements reached ₹1,235 crore, representing a 44% growth compared to Q1 FY26.
Net Interest Income (NII) increased to ₹219 crore, up 39% YoY from ₹158 crore.
Weighted average cost of funds improved by 80 basis points YoY, declining to 9.9%.
Micro LAP segment showed strong momentum with 24% QoQ growth in the retail loan portfolio.
Branch network expanded to 468 locations across 24 states, adding 14 new branches in the quarter.
👀 What to Watch
Investors should monitor the stabilization of asset quality (GNPA at 4.84%) and the company's ability to maintain disbursement momentum in the high-yield Micro LAP segment while keeping credit costs under control.
25% PAT Growth to ₹550 Cr in Q1 FY27; Underwriting Profit Surges to ₹111 Cr
Star Health reported a strong Q1 FY27 with Profit After Tax (PAT) rising 25% YoY to ₹550 Cr, driven by a 19% growth in Gross Written Premium (GWP) to ₹4,287 Cr. The company achieved a significant turnaround in underwriting profitability, with the underwriting result jumping to ₹111 Cr from ₹16 Cr in the previous year. The Combined Insurance Service Ratio (CISR) improved to 97.0% from 98.7%, reflecting better cost management and a lower loss ratio of 67.5%. Retail fresh business grew by 37%, supported by a massive 142% growth in the D2C channel.
Confidence: HIGH
What changedThe company transitioned from marginal underwriting profitability to a more substantial contribution (₹111 Cr) while maintaining high double-digit premium growth and improving its loss ratio.
Why it mattersImproved underwriting margins and lower loss ratios (67.5% vs 68.5%) indicate better risk selection and operational efficiency, which are critical for a standalone health insurer's long-term ROE and valuation.
PAT (Q1 FY27): ₹550 CrGWP Growth (YoY): 19%Underwriting Result: ₹111 CrCombined Insurance Service Ratio: 97.0%D2C Fresh GWP Growth: 142%PAT vs TTM PAT: 98.7%
📅 Short termPositive market reaction is likely as the company beat underwriting expectations and showed strong growth in fresh retail premiums.
📈 Long termStructural improvement in the distribution mix (D2C growth) and agency productivity (8.5 lakh agents) could lead to sustained ROE expansion, which was 22.3% (annualized) this quarter.
⚠ Risk flags
- Dependency on hospital network pricing
- Potential claims inflation if loss ratios revert above 70%
- Regulatory shifts in Banca growth channels
Key Highlights
Gross Written Premium (GWP) grew 19% YoY to ₹4,287 Cr for the quarter ended June 30, 2026
Profit After Tax (PAT) increased by 25% to ₹550 Cr compared to ₹438 Cr in Q1 FY26
Underwriting Result improved significantly to ₹111 Cr from ₹16 Cr in the same period last year
Retail Fresh GWP saw a robust 37% YoY growth, reaching ₹730 Cr
Combined Insurance Service Ratio (CISR) improved to 97.0% from 98.7% YoY, indicating better operational efficiency
👀 What to Watch
Monitor the sustainability of the improved CISR (below 100% indicates underwriting profit) and the growth trajectory of the high-margin D2C channel, which grew 142% YoY.
₹550 Cr PAT in Q1 FY27, up 25% YoY; Underwriting Profit jumps 6x to ₹111 Cr
Star Health reported a robust start to FY27 with PAT rising 25% YoY to ₹550 Cr, which is nearly 99% of its total FY26 PAT in just one quarter. Underwriting profit saw a massive jump to ₹111 Cr from ₹16 Cr in the previous year, driven by disciplined risk selection. Gross Written Premium (GWP) grew 19% YoY to ₹4,287 Cr, with fresh retail health GWP showing a strong 37% growth. The Combined Insurance Service Ratio (CISR) improved to 97.0% from 98.7%, indicating better operational efficiency and claims management.
Confidence: HIGH
What changedStar Health has significantly improved its underwriting profitability and claims settlement efficiency, leading to a quarterly PAT that almost matches its entire previous year's profit.
Why it mattersThe sharp rise in underwriting profit and improvement in CISR suggest the company is successfully repricing its portfolio and managing claims inflation, which are critical for long-term profitability in the health insurance sector.
Q1 FY27 PAT: ₹550 CrQ1 PAT vs FY26 Annual PAT: 98.7%Underwriting Profit: ₹111 CrGWP Growth (YoY): 19%Combined Insurance Service Ratio: 97.0%Fresh Retail GWP Growth: 37%
📅 Short termThe stock is likely to react positively to the significant earnings beat and the sharp improvement in underwriting margins.
📈 Long termThe structural shift towards digital sourcing (97% of fresh policies) and expansion of the agent network to 8.5 lakh+ positions the company well to maintain its 32-33% retail market share.
⚠ Risk flags
- Dependency on hospital network pricing
- Potential claims inflation if loss ratios exceed 70%
Key Highlights
Profit After Tax (PAT) increased 25% YoY to ₹550 Cr in Q1 FY27.
Underwriting Profit grew 6x to ₹111 Cr compared to ₹16 Cr in Q1 FY26.
Fresh Retail Health GWP surged 37% YoY to ₹730 Cr.
Combined Insurance Service Ratio (CISR) improved by 170 bps to 97.0%.
Digital D2C channel sales grew 142% YoY, now contributing 16% of fresh retail sales.
👀 What to Watch
Investors should monitor the sustainability of the improved 97% Combined Insurance Service Ratio (CISR) and the continued growth in the high-margin retail segment. Watch for the execution of the agent expansion plan to 1 million to see if it maintains the current 19% GWP growth momentum.
Rs 438 Cr Q1 PAT: Star Health Adopts Ind AS Accounting Standards
Star Health reported a flat Net Profit of Rs 438.18 Cr for Q1 FY27, matching the restated Ind AS profit from the same quarter last year. Insurance revenue grew 13.4% YoY to Rs 4,917.20 Cr. This quarter marks the mandatory transition to Ind AS 117 (Insurance Contracts) and Ind AS 109 (Financial Instruments), which significantly alters how liabilities and financial assets are valued. The company noted that seasonality, particularly the monsoon, typically leads to higher claims in the upcoming months.
Confidence: HIGH
What changedThe company transitioned its financial reporting from Indian GAAP to Ind AS, specifically adopting Ind AS 117 for insurance contracts and Ind AS 109 for financial instruments.
Why it mattersThe transition to Ind AS 117 is a major structural change in how insurance companies recognize revenue and liabilities, aligning Star Health with global accounting standards and providing a more granular view of insurance service results.
Insurance Revenue (Q1): Rs 4,917.20 CrNet Profit (Q1): Rs 438.18 CrRevenue vs TTM Revenue: 27.6%Investment Income: Rs 643.59 CrYoY Revenue Growth: 13.4%
📅 Short termThe stock may see neutral to slightly cautious sentiment as the market adjusts to the new Ind AS reporting format and the flat YoY profit performance.
📈 Long termThe adoption of Ind AS 117 provides better transparency into the profitability of the insurance book over time, though the company's focus on retail health and agent expansion remains the primary long-term growth driver.
⚠ Risk flags
- Seasonality (higher claims expected in monsoon)
- Claims inflation
- Accounting complexity during Ind AS transition
Key Highlights
Insurance revenue increased 13.4% YoY to Rs 4,917.20 Cr from Rs 4,336.42 Cr
Net Profit remained flat at Rs 438.18 Cr compared to the restated Ind AS figure for Q1 FY26
Investment income rose to Rs 643.59 Cr for the quarter
Incurred claims for the quarter stood at Rs 2,951.43 Cr
Granted 10,90,409 ESOP options and allotted 1,73,407 equity shares during the period
👀 What to Watch
Investors should focus on the 'Combined Ratio' and claims performance in the next quarter (Q2), as the company explicitly flagged higher seasonal claims during the monsoon. Monitor how the transition to Ind AS 117 affects long-term margin reporting.
Star Health Q1 Revenue Up 13.4% YoY to Rs 4,917 Cr; 4,700 NCDs to be Redeemed
Star Health reported Q1 FY27 insurance revenue of Rs 4,917.2 Cr, a 13.4% increase from Rs 4,336.4 Cr in the same quarter last year. Incurred claims for the quarter stood at Rs 2,951.4 Cr, reflecting a claims-to-revenue ratio of approximately 60%. The board also approved the full redemption of 4,700 listed NCDs in two tranches by October 2026 and initiated the reclassification of 97 promoter group entities (including the Estate of Late Rakesh Jhunjhunwala) to the public category.
Confidence: HIGH
What changedThe company released its Q1 FY27 financial results, set a timeline for debt redemption, and began simplifying its promoter shareholding structure.
Why it mattersThe results show steady top-line growth in the retail health segment, while the NCD redemption will reduce future interest obligations and the promoter reclassification cleans up the cap table.
Insurance Revenue (Q1 FY27): Rs 4,917.2 CrInsurance Revenue (Q1 FY26): Rs 4,336.4 CrIncurred Claims: Rs 2,951.4 CrTotal NCDs for Redemption: 4,700 unitsRevenue vs TTM Revenue: ~27.6%
📅 Short termThe stock may see neutral to slightly positive movement as the market digests the 13.4% revenue growth and the impact of debt reduction.
📈 Long termThe company's focus on expanding its agent network to 1 million and maintaining its 32-33% retail health market share remains the primary long-term value driver.
⚠ Risk flags
- Claims inflation
- High P/E ratio of 63.0 relative to historical PAT growth
- Regulatory shifts in banking distribution (Banca growth)
Key Highlights
Insurance revenue grew to Rs 4,917.2 Cr in Q1 FY27 from Rs 4,336.4 Cr in Q1 FY26
Incurred claims for the quarter ended June 30, 2026, were Rs 2,951.4 Cr
Board approved redemption of 4,000 NCDs on September 30, 2026, and 700 NCDs on October 29, 2026
Reclassification of 97 promoter group entities to the public category was approved, subject to member consent
Investment income for the quarter stood at Rs 643.6 Cr (Rs 64,359 lakhs)
👀 What to Watch
Investors should monitor the full financial statement to assess the Combined Ratio and Net Profit Margin, as the current revenue growth of 13.4% is slightly below the company's long-term target of 16%.
IndoStar to Raise up to ₹6,000 Cr via NCDs; Appoints S.R. Batliboi as Auditor
IndoStar Capital Finance has approved a significant fundraise of up to ₹6,000 crore through Non-Convertible Debentures (NCDs) via private placement, subject to shareholder approval. This proposed limit is substantial, representing approximately 233% of the company's current market capitalization (₹2,571 Cr). The board also recommended appointing S. R. Batliboi & Co. LLP as statutory auditors for a three-year term, following RBI's mandatory rotation norms. Additionally, the company confirmed that ₹600 crore raised in April 2026 has been fully utilized for onward lending.
Confidence: HIGH
What changedThe company has initiated a fresh annual borrowing limit of ₹6,000 Cr and is rotating its statutory auditors from MSKA & Associates to S. R. Batliboi & Co. LLP to comply with RBI guidelines.
Why it mattersThe large fundraise limit provides the necessary liquidity to execute IndoStar's strategic shift from corporate lending to a retail-focused model (Used CV and Micro LAP). The auditor change to a 'Big 4' affiliate enhances reporting credibility.
Proposed NCD Fundraise Limit: ₹6,000 crFundraise vs Market Cap: ~233%Fundraise vs TTM Revenue: ~232%NCDs raised in April 2026: ₹600 crAuditor Appointment Term: 3 years
📅 Short termThe announcement of a large fundraise limit is likely to be viewed positively as it signals growth intent and liquidity readiness for the upcoming quarters.
📈 Long termThe structural shift toward a granular retail portfolio, backed by significant debt headroom, could re-rate the business if the company successfully manages asset quality (GNPA was 4.52% in previous filings).
⚠ Risk flags
- High dependency on debt market conditions to raise the proposed ₹6,000 Cr
- Execution risk in transitioning to a 100% retail-focused model
- Asset quality monitoring in the Used CV and Micro LAP segments
Key Highlights
Proposed issuance of Non-Convertible Debentures (NCDs) for an amount not exceeding ₹6,000 crore in a year.
Appointment of S. R. Batliboi & Co. LLP as Statutory Auditors for a 3-year term starting from the 17th AGM.
Full utilization of ₹600 crore raised via three NCD tranches on April 23, 2026, for onward lending purposes.
17th Annual General Meeting (AGM) scheduled for September 25, 2026, to seek shareholder approvals.
Subsidiary IndoStar Asset Advisory reported a net profit of ₹3.16 lakhs for the quarter ended June 30, 2026.
👀 What to Watch
Investors should monitor the shareholder approval for the ₹6,000 Cr NCD limit at the upcoming AGM on September 25, 2026, and track the company's ability to raise this debt at competitive interest rates to fuel its retail lending shift.
₹6,000 Cr NCD limit approved by IndoStar Board; Q1 FY27 results released
IndoStar Capital Finance has approved a significant fundraise limit of ₹6,000 crore through Non-Convertible Debentures (NCDs), representing approximately 233% of its current market capitalization. The company also reported its Q1 FY27 financial results and confirmed the full utilization of ₹600 crore raised in April 2026 for onward lending. Additionally, the board has proposed the appointment of S. R. Batliboi & Co. LLP as statutory auditors for a three-year term. These proposals are subject to shareholder approval at the upcoming AGM on September 25, 2026.
Confidence: HIGH
What changedThe company has set a massive new debt-raising ceiling and initiated a change in its statutory auditors as per RBI guidelines.
Why it mattersThe ₹6,000 crore NCD limit provides the necessary liquidity to pivot from corporate lending to high-yield retail segments like Used CV and Micro LAP. This scale of fundraise is substantial relative to the company's ₹3,778 crore net worth.
NCD Issuance Limit: ₹6,000 croreLimit vs Market Cap: ~233.8%Limit vs Net Worth: ~158.8%April 2026 NCD Raise: ₹600 croreAGM Date: September 25, 2026
📅 Short termThe stock may react to the large fundraise approval and the transition to a top-tier auditor, though the specific Q1 earnings performance will be the primary driver in the coming days.
📈 Long termIf the company successfully raises and deploys the ₹6,000 crore into its 18.1% yield retail book, it could significantly re-rate the business from its current 0.7x P/B valuation.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High dependency on debt market conditions for the ₹6,000 crore fundraise
- History of asset quality volatility (GNPA at 4.52%)
- Recent large quarterly loss in March 2026
Key Highlights
Board approved a fresh NCD issuance limit of ₹6,000 crore for the year, subject to shareholder approval.
Fully utilized ₹600 crore raised via NCDs in April 2026 for onward lending to customers.
Proposed appointment of S. R. Batliboi & Co. LLP as Statutory Auditors for a 3-year term starting from the 17th AGM.
17th Annual General Meeting (AGM) scheduled for September 25, 2026, to ratify fundraise and auditor changes.
Subsidiary IndoStar Asset Advisory reported a small net profit of ₹3.16 lakhs for the quarter ended June 30, 2026.
👀 What to Watch
Investors should monitor the detailed Q1 FY27 P&L to verify if the company has stabilized after the ₹424 crore loss reported in March 2026. The execution of the ₹6,000 crore fundraise will be critical for supporting the company's targeted 40-50% growth rate in retail segments.
Rs 2.00 Final Dividend: Five-Star Business Finance Sets July 31 as Record Date
Five-Star Business Finance has announced a final dividend of Rs 2.00 per equity share for FY 2025-26, representing a 200% payout on the face value of Rs 1. The record date to determine eligibility is July 31, 2026, with the payment scheduled to be completed by September 29, 2026, following shareholder approval at the AGM on August 31, 2026. The company has also detailed Tax Deduction at Source (TDS) procedures, requiring shareholders to submit relevant tax exemption documents by August 10, 2026. Based on the current market cap, the total estimated payout is approximately Rs 58.88 Cr, which is roughly 5.4% of the TTM PAT of Rs 1,098 Cr.
Confidence: HIGH
What changedThe company has established the specific timeline (Record Date, AGM Date, Payment Date) and tax documentation requirements for the FY26 final dividend.
Why it mattersThis is a routine distribution of profits to shareholders; the estimated payout of ~Rs 59 Cr is well-covered by the company's TTM PAT of Rs 1,098 Cr.
Dividend per share: Rs 2.00Record Date: July 31, 2026Estimated Payout vs TTM PAT: ~5.4%TDS Rate (with PAN): 10%TDS Rate (without PAN): 20%
📅 Short termThe stock may see minor price adjustments around the ex-dividend date; focus will be on administrative compliance for tax withholding.
📈 Long termLimited structural impact; routine dividend reflects the company's ability to generate consistent profits and share them with investors.
Key Highlights
Final dividend of Rs 2.00 per equity share recommended for the financial year 2025-26.
Record date for determining eligible shareholders is fixed as July 31, 2026.
Standard TDS rate of 10% applies to resident individuals with valid PAN, increasing to 20% if PAN is missing or inoperative.
Exemption from TDS for resident individuals if the total dividend for the year does not exceed Rs 10,000.
Cut-off date for submitting tax-related declarations (Form 121, etc.) is August 10, 2026.
👀 What to Watch
Shareholders should ensure their PAN is linked with Aadhaar and bank account details are updated with their Depository Participant before the July 31 record date to avoid 20% TDS.
₹1,496 Cr Record Disbursements: Five-Star Finance Q1FY27 AUM Grows 10% YoY
Five-Star Business Finance reported its highest-ever quarterly disbursements of ₹1,496.4 Cr in Q1FY27, a 23% sequential increase. Assets Under Management (AUM) reached ₹13,721.8 Cr, growing 10% year-on-year. While Profit After Tax (PAT) grew marginally by 1% QoQ to ₹271.4 Cr, asset quality showed slight improvement with 30+ DPD reducing to 12.38% from 12.69%. The company maintained industry-leading profitability with a Net Interest Margin (NIM) of 19.97% and a Return on Average AUM of 8.11%.
Confidence: HIGH
What changedThe company hit a record high in quarterly disbursements and successfully lowered its cost of funds by 15 bps sequentially despite tight liquidity conditions.
Why it mattersThe record disbursements signal a return to a strong growth trajectory in the secured MSME segment, while maintaining high NIMs (19.97%) and ROA (8.11%) supports its premium valuation.
Quarterly Disbursements: ₹1,496.4 CrTotal AUM: ₹13,721.8 CrNet Interest Margin (NIM): 19.97%Gross NPA: 3.46%Return on Average AUM: 8.11%Cost of Funds: 8.80%
📅 Short termThe stock may react positively to the record disbursement figures and the sequential improvement in asset quality and cost of funds.
📈 Long termThe company continues to demonstrate a highly profitable niche model in secured MSME lending with low leverage (2.07x) and strong return ratios, though credit costs remain a key monitorable.
⚠ Risk flags
- Credit costs remain elevated at 1.85% of average loan portfolio
- High 30+ DPD at 12.38% indicates potential future slippages
Key Highlights
Achieved historical best quarterly disbursements of ₹1,496.4 Cr, up 16% YoY and 23% QoQ.
Total AUM grew to ₹13,721.8 Cr, a 10% increase compared to June 2025.
Cost of funds on the book improved to 8.80% from 8.95% in the previous quarter.
Asset quality metrics improved with 30+ DPD dropping 31 bps sequentially to 12.38%.
Branch network expanded to 856 locations, adding 12 new branches during the quarter.
👀 What to Watch
Watch for the sustainability of record disbursement levels in upcoming quarters and whether the reduction in 30+ DPD leads to a meaningful decline in Gross NPA from the current 3.46%.
₹1,496 Cr Record Disbursements in Q1FY27; AUM Grows 10% YoY to ₹13,722 Cr
Five-Star Business Finance reported its highest-ever quarterly disbursements of ₹1,496 Cr in Q1FY27, up 23% sequentially. While AUM grew 10% YoY to ₹13,722 Cr, profitability remained nearly flat with PAT at ₹271 Cr (+2% YoY). Asset quality showed slight deterioration as Gross Stage 3 assets rose to 3.46% from 3.37% in the previous quarter. Despite this, the company maintained strong Net Interest Margins (NIM) at 19.97% and reduced its cost of funds by 15 bps to 8.80%.
Confidence: HIGH
What changedThe company achieved record-high disbursements but experienced a continued uptick in non-performing assets (Stage 3) and a significant year-on-year decline in RoE and RoA.
Why it mattersThe record disbursements indicate strong demand and successful branch expansion, but rising NPAs suggest stress in the underlying MSME borrower base, which could impact long-term profitability if not contained.
AUM: ₹13,722 CrQuarterly Disbursements: ₹1,496 CrGross Stage 3 Assets: 3.46%Net Interest Margin: 19.97%Cost of Funds: 8.80%AUM vs Market Cap: ~87%
📅 Short termThe market may focus on the record disbursement figures as a sign of growth recovery, though the slight rise in NPAs and flat PAT growth could limit immediate upside.
📈 Long termThe company aims for 20% AUM growth in FY27. Long-term value depends on its ability to scale the higher ticket size (₹3-10 lakh) loans to improve asset quality while maintaining its industry-leading NIMs.
⚠ Risk flags
- Rising Gross Stage 3 assets (up 100 bps YoY)
- Declining Return on Equity (down 211 bps YoY)
- Seasonally weak collection efficiency (97.9%)
Key Highlights
Record quarterly disbursements of ₹1,496 Cr, representing 23% sequential and 16% YoY growth.
AUM reached ₹13,722 Cr, a 10% increase over June 2025.
Gross Stage 3 assets increased to 3.46% from 3.37% in Q4FY26 and 2.46% in Q1FY26.
Cost of funds on the overall borrowing book improved to 8.80% from 8.95% in the previous quarter.
Return on Equity (RoE) compressed to 14.46% compared to 16.57% in the same quarter last year.
👀 What to Watch
Investors should monitor the 'normalization' of NPA levels over the next two quarters as guided by management to see if slippages truly taper off. The disconnect between high disbursement growth (16% YoY) and low PAT growth (2% YoY) warrants a closer look at credit costs and provisioning in upcoming results.
Q1 Net Profit at ₹271.4 Cr; Joint Auditor Proposed as Assets Cross ₹15,000 Cr
Five-Star Business Finance reported a steady Q1 FY27 with a net profit of ₹271.41 Cr, showing modest growth from ₹269.00 Cr in the preceding quarter. Total income rose to ₹838.74 Cr, a 6% increase compared to ₹791.19 Cr in the same quarter last year. A significant regulatory step was taken with the proposal to appoint M/s Suri & Co as Joint Statutory Auditors, a mandatory requirement by the RBI for NBFCs with asset sizes exceeding ₹15,000 Cr. The board also appointed Mr. Sreeram Ranganathan Iyer as an Independent Director, bringing extensive international banking experience.
Confidence: HIGH
What changedThe company reported its Q1 FY27 financial results and initiated the process to appoint joint statutory auditors to comply with RBI's large NBFC governance norms.
Why it mattersThe transition to joint auditing confirms the company has reached a significant scale (>₹15,000 Cr assets), while the steady earnings reflect stability in the secured MSME lending segment despite rising credit costs.
Q1 Net Profit: ₹271.41 CrQ1 Total Income: ₹838.74 CrYoY Revenue Growth: 6.0%Impairment Costs: ₹61.82 CrBasic EPS: ₹9.19
📅 Short termThe stock is likely to remain range-bound as the earnings growth was modest and impairment costs showed an upward trend.
📈 Long termThe company's expansion to 748 branches and focus on resilient borrower profiles (higher ticket sizes) support its long-term growth target of 15-17%.
⚠ Risk flags
- Rising impairment costs (up 29% YoY)
- Concentration in MSME segment which is sensitive to economic cycles
Key Highlights
Net Profit for Q1 FY27 stood at ₹271.41 Cr, a 2% YoY increase from ₹266.00 Cr.
Total Revenue from operations reached ₹828.98 Cr, up 5.4% from ₹786.68 Cr in Q1 FY26.
Impairment on financial instruments rose to ₹61.82 Cr, compared to ₹47.78 Cr in the year-ago period.
Proposed appointment of M/s Suri & Co as Joint Statutory Auditors for a 3-year term starting from the 42nd AGM.
Basic EPS for the quarter recorded at ₹9.19, slightly higher than ₹9.12 in the previous quarter.
👀 What to Watch
Investors should monitor the trend in impairment costs, which rose 29% YoY, and track the execution of the company's strategy to shift toward higher ticket size loans (₹3-10 lakh) to maintain asset quality.
Blue Star Wins Arbitration; Rs 461.74 Cr Claim by W.J. Towell & Co Dismissed
Blue Star Limited has received a favorable award from the International Chamber of Commerce (ICC) dismissing all claims filed by W.J. Towell & Co LLC (WJT). The revised claim amount was OMR 21,180,748 (approx. Rs 461.74 crore) plus 7% interest, which represented nearly 100% of Blue Star's TTM Net Profit of Rs 462 crore. The arbitrator has dismissed the entire claim, though the final award regarding interest and legal costs is still reserved for a future date. This outcome removes a significant contingent liability that had been pending since early 2024.
Confidence: HIGH
What changedA major international arbitration proceeding against Blue Star has concluded with a total dismissal of all claims made by the counterparty.
Why it mattersThe claim amount was highly material, roughly equal to the company's entire annual profit (TTM PAT Rs 462 cr). Its dismissal prevents a potential massive one-time hit to the bottom line and protects the company's net worth.
Dismissed Claim Amount: Rs 461.74 crClaim vs TTM PAT: 99.94%Claim vs Net Worth: 15.09%Interest Rate Claimed: 7%
📅 Short termThe stock is likely to react positively as the market prices out the risk of a significant legal payout.
📈 Long termThe resolution protects the company's capital for its stated 20-25% growth strategy and expansion into US/Europe markets.
⚠ Risk flags
- Potential for counterparty to challenge the award in local courts
Key Highlights
Arbitrator dismissed the total revised claim of OMR 2,11,80,748 (approx. Rs 461.74 crore).
The original claim filed in April 2024 was OMR 1,03,18,000 (approx. Rs 223.60 crore).
The dispute related to a Shareholders’ Agreement dated October 1, 2015, for managing Blue Star Oman Electro Mechanical Company.
The favorable award was received by the company on July 23, 2026.
The claim amount of Rs 461.74 crore is equivalent to approximately 15.1% of the company's Net Worth (Rs 3,060 crore).
👀 What to Watch
Investors should note the removal of this significant legal overhang; the next step is to wait for the final award regarding the recovery of legal costs and interest.
₹400 Crore NCD Allotment at 9.15% Coupon to Support Retail Lending Growth
IndoStar Capital Finance has successfully allotted 40,000 senior, secured, redeemable NCDs totaling ₹400 crore via private placement. The issuance is split into two series of ₹200 crore each with tenors of 25 and 28 months, both carrying a 9.15% annual coupon. This fundraise represents approximately 16.1% of the company's market capitalization, providing significant liquidity for its retail-focused lending strategy. The move follows the company's strategic shift toward Used Commercial Vehicles (CV) and Micro Loan Against Property (LAP) segments.
Confidence: HIGH
What changedIndoStar has secured ₹400 crore in fresh debt capital through the private placement of senior secured Non-Convertible Debentures.
Why it mattersFor an NBFC, consistent access to debt markets is critical for lending operations; this fundraise supports the company's transition from corporate to retail lending and provides a clear cost-of-funds benchmark at 9.15%.
Total Issue Size: ₹400 croreCoupon Rate: 9.15%Issue vs Market Cap: ~16.1%Face Value per NCD: ₹1,00,000Series XXXV Maturity Date: November 23, 2028
📅 Short termThe successful allotment confirms market confidence in the company's debt-raising ability despite a significant loss reported in March 2026.
📈 Long termThis capital supports the structural shift toward a granular retail portfolio, which is expected to reduce client concentration risks over the next 2-3 years.
⚠ Risk flags
- Dependency on debt funding lines
- Asset quality risks (GNPA at 4.52%)
- Recent quarterly volatility (₹424 Cr loss in Mar 2026)
Key Highlights
Allotment of 40,000 NCDs with a face value of ₹1,00,000 each, totaling ₹400 crore.
Fixed coupon rate of 9.15% per annum, with interest payable annually.
Series XXXIV (₹200 Cr) has a 25-month tenor maturing on August 23, 2028.
Series XXXV (₹200 Cr) has a 28-month tenor maturing on November 23, 2028.
Fundraise magnitude is ~16.1% of the current market capitalization of ₹2,479 crore.
👀 What to Watch
Investors should monitor the company's ability to deploy this capital into high-yielding retail assets while improving asset quality, specifically tracking the GNPA which stood at 4.52%.
₹5 Final Dividend Announced; 35th AGM Scheduled for August 14, 2026
Strides Pharma Science Limited has scheduled its 35th Annual General Meeting (AGM) for August 14, 2026. The company has recommended a final dividend of ₹5 per equity share (50% of face value) for FY2025-26, with a record date of July 31, 2026. Key agenda items include the re-appointment of Founder Arun Kumar as a Director and a special resolution to pay commissions up to ₹50 lakh per Non-Executive Director even in years with inadequate profits. The company reported a TTM PAT of ₹389 Cr on a revenue base of ₹3636 Cr.
Confidence: HIGH
What changedThe company has formalized the dividend payout, set the record date, and scheduled the annual shareholder meeting for FY26.
Why it mattersThe dividend provides a direct cash return to shareholders (approx. 0.47% yield at current price), while the re-appointment of the founder ensures leadership continuity.
Final Dividend: ₹5 per shareRecord Date: July 31, 2026AGM Date: August 14, 2026NED Commission Cap: ₹50,00,000 per yearDividend Yield: 0.47%
📅 Short termThe stock may experience minor price adjustments around the July 31 record date as it goes ex-dividend.
📈 Long termLimited structural impact as this is a routine annual administrative and dividend filing.
⚠ Risk flags
- Special resolution for director commissions during profit inadequacy may face scrutiny from proxy advisory firms.
Key Highlights
Final dividend of ₹5 per equity share of face value ₹10 recommended for FY26.
Record date for dividend eligibility is fixed for July 31, 2026.
AGM to be held on August 14, 2026, via Video Conference/Other Audio-Visual Means.
Proposed commission cap of ₹50,00,000 per Non-Executive Director in case of profit inadequacy.
Founder Arun Kumar (DIN: 00084845) is seeking re-appointment as a Non-Executive Director.
👀 What to Watch
Investors should ensure their shareholding is reflected in the records by the July 31, 2026 record date to be eligible for the ₹5 dividend. Watch for the voting results on the special resolution regarding director commissions on or before August 18, 2026.
₹5 Final Dividend: Strides Pharma Sets July 31, 2026, as Record Date
Strides Pharma Science has fixed July 31, 2026, as the record date for a final dividend of ₹5 per share for FY26. This payout represents 50% of the ₹10 face value and follows a recovery in profitability with a TTM PAT of ₹389 Cr. The dividend is subject to shareholder approval at the 35th Annual General Meeting (AGM) scheduled for August 14, 2026. At the current market price of ₹1061.9, the dividend yield stands at approximately 0.47%.
Confidence: HIGH
What changedThe company has formalized the timeline (Record Date and AGM date) for the distribution of its previously recommended FY26 final dividend.
Why it mattersThe dividend confirms a return to shareholder distributions supported by a TTM PAT of ₹389 Cr, although the yield remains low at 0.47%.
Dividend per share: ₹5Dividend Yield: ~0.47%Record Date: 31-Jul-2026AGM Date: 14-Aug-2026Face Value: ₹10TTM PAT: ₹389 Cr
📅 Short termThe stock may see minor price adjustments around the ex-dividend date, though the low yield suggests limited volatility from this specific event.
📈 Long termLimited structural impact; the dividend is a routine distribution of earnings.
Key Highlights
Final dividend of ₹5 per equity share recommended for the financial year ended March 31, 2026.
Record date for determining shareholder entitlement is fixed for July 31, 2026.
35th Annual General Meeting (AGM) to be held on August 14, 2026, via video conferencing.
Dividend payment to be completed within 30 days of shareholder approval at the AGM.
Dividend payout represents 50% of the face value of ₹10 per share.
👀 What to Watch
Investors must hold the shares before the July 31 record date to be eligible for the payout. Monitor the August 14 AGM for management updates on the target of 60 new US product launches.
Sept 30, 2026: Prostarm Delays Production at 1.2 GWh BESS and Gujarat Facilities
Prostarm Info Systems has announced a delay in the commencement of commercial production at its two new manufacturing facilities in Haryana and Gujarat, now expected by September 30, 2026. The Haryana plant is a significant 1.2 GWh Battery Energy Storage System (BESS) facility, while the Gujarat plant is also under development. The company cited geopolitical conditions and resource availability as reasons for the delay, despite factory buildings being 'substantially ready.' This delay is notable as the company is working to execute a large order book of approximately ₹1,100 Cr, which is roughly 3x its TTM revenue.
Confidence: HIGH
What changedThe timeline for starting commercial operations at two major new manufacturing plants has been pushed back from previous undisclosed or earlier targets to September 30, 2026.
Why it mattersThe 1.2 GWh BESS facility is a major capacity addition intended to drive the company's growth strategy; a delay postpones the revenue realization from its large ₹1,100 Cr order book.
BESS Capacity: 1.2 GWhRevised Production Deadline: September 30, 2026Order Book (Sept 2025): ₹1,100 CrOrder Book vs TTM Revenue: ~303%TTM Revenue: ₹363 Cr
📅 Short termThe stock may face downward pressure as the market adjusts for delayed revenue growth and potential cost overruns due to the extended timeline.
📈 Long termWhile the delay is a setback, the structural shift toward BESS and the large order book suggest long-term potential if the company successfully commissions the 1.2 GWh capacity by late 2026.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk due to timeline slippage
- Supply chain vulnerability to geopolitical factors
- High working capital intensity
Key Highlights
Commercial production at Haryana and Gujarat facilities delayed to on or before September 30, 2026
The Haryana facility at Reliance MET, Jhajjar, features a 1.2 GWh Battery Energy Storage System (BESS) capacity
Company is managing a robust order book of approximately ₹1,100 Cr as of September 2025
Current TTM revenue stands at ₹363 Cr, making the new capacity critical for future growth
Delay attributed to external factors and geopolitical conditions impacting resource procurement
👀 What to Watch
Investors should monitor the company's quarterly revenue execution from existing units to see if the ₹1,100 Cr order book can be serviced without the new capacity, and watch for any further timeline slippages beyond September 2026.
Blue Star Proposes ₹8.5 Final Dividend; 78th AGM Scheduled for August 6, 2026
Blue Star Limited has issued a notice for its 78th Annual General Meeting (AGM) to be held on August 6, 2026. The primary agenda includes the declaration of a final dividend of ₹8.5 per equity share (face value ₹2) for FY26. The company has fixed July 17, 2026, as the record date for dividend eligibility. With a TTM revenue of ₹12,124 Cr and a PAT of ₹462 Cr, the proposed dividend represents a payout based on a stable financial performance in the previous fiscal year.
Confidence: HIGH
What changedThe company has formalized the date for its 78th AGM and confirmed the specific dividend amount and record date for shareholders.
Why it mattersThis is a routine but significant event for shareholders to receive their annual return on investment and vote on key items like director re-appointments and auditor remuneration.
Final Dividend: ₹8.5 per shareRecord Date: July 17, 2026Dividend Yield (approx): 0.50%TTM Revenue: ₹12,124 CrTTM PAT: ₹462 Cr
📅 Short termThe stock may see minor price adjustments around the ex-dividend date (typically one day before the record date) as the market factors in the ₹8.5 payout.
📈 Long termLimited; this is a routine administrative filing. Long-term focus remains on the company's expansion into US/Europe markets and market share gains in the Room AC segment.
Key Highlights
Final dividend of ₹8.5 per equity share (face value ₹2) proposed for FY26
Record date for dividend eligibility set for July 17, 2026
78th AGM scheduled for August 6, 2026, at 3:30 p.m. IST via Video Conferencing
Remote e-voting period starts August 1, 2026, and ends August 5, 2026
TTM Revenue of ₹12,124 Cr with an Operating Profit Margin of 7.6%
👀 What to Watch
Investors should note the record date of July 17, 2026, to be eligible for the ₹8.5 dividend. The upcoming Q1 FY27 results in August 2026 will be the next major catalyst to monitor for growth execution.
₹8.5 Dividend Proposed; Blue Star Schedules 78th AGM for August 6, 2026
Blue Star Limited has issued the notice for its 78th Annual General Meeting (AGM) scheduled for August 6, 2026. The primary agenda includes the declaration of a final dividend of ₹8.5 per equity share (425% of face value) for FY26. The company has fixed July 17, 2026, as the record date for determining dividend eligibility. This follows a financial year where the company reported TTM revenue of ₹12,124 Cr and a PAT of ₹462 Cr.
Confidence: HIGH
What changedThe company has formalized the date for its 78th AGM and confirmed the specific dividend amount and record date for FY26.
Why it mattersThis is a routine but significant event for shareholders as it confirms the timing of cash returns (dividend) and provides the full Integrated Annual Report for detailed operational review.
Final Dividend: ₹8.5 per shareDividend Yield (at current price): 0.50%Record Date: July 17, 2026TTM Revenue: ₹12,124 CrTTM PAT: ₹462 Cr
📅 Short termThe stock may see minor price adjustments around the July 17 record date as it goes ex-dividend.
📈 Long termLimited structural significance from this filing; long-term focus remains on the company's 20-25% growth target and market share expansion in the Room AC segment.
Key Highlights
Final dividend of ₹8.5 per equity share of ₹2 face value proposed for FY26
Record date for dividend eligibility set for July 17, 2026
78th AGM to be held on August 6, 2026, via Video Conferencing
Remote e-voting period scheduled from August 1 to August 5, 2026
TTM Revenue of ₹12,124 Cr and PAT of ₹462 Cr provide the financial backdrop for the payout
👀 What to Watch
Investors should note the record date of July 17, 2026, to be eligible for the ₹8.5 dividend. Review the Integrated Annual Report for updates on the US/Europe export strategy and MedTech segment recovery.
